Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Capital Expenditures (2021 - 2025)

Prime Medicine's Capital Expenditures history spans 5 years, with the latest figure at -$4.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 5.1% year-over-year to -$4.1 million; the TTM value through Dec 2025 reached $114000.0, down 90.12%, while the annual FY2025 figure was $114000.0, 90.12% down from the prior year.
  • Capital Expenditures reached -$4.1 million in Q4 2025 per PRME's latest filing, down from $247000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2023 to a low of -$5.6 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $467470.6, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Capital Expenditures: surged 8193.94% in 2023, then crashed 152.97% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$3.0 million in 2021, then skyrocketed by 103.28% to $99000.0 in 2022, then soared by 8193.94% to $8.2 million in 2023, then plummeted by 152.97% to -$4.3 million in 2024, then increased by 5.1% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Capital Expenditures are -$4.1 million (Q4 2025), $247000.0 (Q3 2025), and $1.6 million (Q2 2025).